# A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density

> **NCT00293813** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 247 (actual)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** Alendronate
- **DRUG:** Denosumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00293813
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-03
- **Final completion:** 2008-08
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2014-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293813, "A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00293813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*